TargetBeta
STEAP2
STEAP2 metalloreductase · also IPCA-1, STAMP1, STMP, PCANAP1 · STEAP family
6 programs in company-led studies act on STEAP2, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| STEAP2-targeting Radioconjugate AZD2287rule | AstraZeneca | phase 2 | 22 running | – | NCIt |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 11 running | CD3E, CD8A | a judged reading |
| Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516 | AstraZeneca | phase 2 | 11 running | – | a judged reading |
| Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754 | AstraZeneca | phase 2 | 11 running | – | a judged reading |
| AZD8359rule | AstraZeneca | phase 2 | 11 running | – | the studies' text |
| Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284 | AstraZeneca | phase 1 | 11 running | – | a judged reading |
Conditions their studies are in
- Prostatic Neoplasms, 6 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 24, 2026STEAP2-targeting Radioconjugate AZD2287 · AstraZeneca · phase 2 · NCT06267729
- Nov 24, 2026Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754 · AstraZeneca · phase 2 · NCT06267729
- Nov 17, 2027AZD8359 · AstraZeneca · phase 2 · NCT07529717
- Jan 18, 2029Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516 · AstraZeneca · phase 2 · NCT07181161
- Mar 29, 2029Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 · AstraZeneca · phase 2 · NCT07192614
- Apr 16, 2029Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284 · AstraZeneca · phase 1 · NCT06879041
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.